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BACKGROUND: Neutropenia is a common adverse reaction of chemotherapy. We assessed whether chemotherapy-induced
neutropenia could be a predictor of survival for patients with non-small-cell lung cancer (NSCLC).
METHODS: A total of 387 chemotherapy-naı ¨ve patients who received chemotherapy (vinorelbine and gemcitabine followed by
docetaxel, or paclitaxel and carboplatin) in a randomised controlled trial were evaluated. The proportional-hazards regression model
was used to examine the effects of chemotherapy-induced neutropenia and tumour response on overall survival. Landmark analysis
was used to lessen the bias of more severe neutropenia resulting from more treatment cycles allowed by longer survival, whereby
patients who died within 126 days of starting chemotherapy were excluded.
RESULTS: The adjusted hazard ratios for patients with grade-1 to 2 neutropenia or grade-3 to 4 neutropenia compared with no
neutropenia were 0.59 (95% confidence interval (CI), 0.36–0.97) and 0.71 (95% CI, 0.49–1.03), respectively. The hazard ratios did
not differ significantly between the patients who developed neutropenia with stable disease (SD), and those who lacked neutropenia
with partial response (PR).
CONCLUSION: Chemotherapy-induced neutropenia is a predictor of better survival for patients with advanced NSCLC. Prospective
randomised trials of early-dose increases guided by chemotherapy-induced toxicities are warranted.
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Chemotherapy is the standard remedy for patients with advanced
cancer and neutropenia is an important dose-limiting toxicity
of anticancer agents. Several studies since the late 1990s have
reported that neutropenia (or leukopenia) that occurs during
chemotherapy is a predictor of significantly longer survival for
patients with breast cancer (Saarto et al, 1997; Cameron et al,
2003). A recent study by Di Maio et al (2005) confirmed the
positive correlation between chemotherapy-induced neutropenia
and increased survival in a pooled analysis of three randomised
trials, which included 1265 patients with advanced non-small-cell
lung cancer (NSCLC). Pallis et al (2008) have also shown the
association between chemotherapy-induced neutropenia and
better clinical outcome for patients with NSCLC. In a prospective
survey of oral fluoropyrimidine S-1 in 1055 patients with advanced
gastric cancer, Yamanaka et al (2007) reported that patients with
moderate (grade-2) neutropenia had the longest survival.
In light of these reports, we have analysed the associations
between the extent of chemotherapy-induced neutropenia, overall
survival and tumour response by reviewing data from a clinical
trial of patients with advanced NSCLC.
MATERIALS AND METHODS
Patients and treatment
A total of 401 chemotherapy-naı ¨ve patients with NSCLC stage IIIB
(positive pleural effusion) or stage IV (no brain metastases), who
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shad Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1, were enrolled in this randomised controlled trial
(Japan Multinational Trial Organization LC00-03) between March
2001 and April 2005. Of 393 eligible patients, information
regarding chemotherapy-induced neutropenia was not available
for six patients. Thus, data from 387 patients were included in this
analysis. These participants were divided into two groups by
treatment. The experimental group (VGD arm, n¼192) received
three cycles of intravenous vinorelbine (25mg/m
2) and gemcita-
bine (1000mg/m
2) administered on days 1 and 8 of each 21 day
cycle, followed by three cycles of single-agent intravenous
docetaxel (60mg/m
2) administered on day 1 of each 21 day cycle.
The standard regimen (PC arm, n¼195) consisted of six cycles of
intravenous paclitaxel (225mg/m
2) plus carboplatin (area under
curve ¼6) infused on day 1 of each 21 day cycle. Details of dose
modifications and reductions have been described previously
(Kubota et al, 2008). The protocol permitted use of granulocyte-
colony-stimulating factor (G-CSF) for patients with grade-3
neutropenia with fever or grade-4 leukopenia or neutropenia,
but did not permit prophylactic use.
Statistical analysis
Neutrophil counts were recorded on day 1, 8 and 15 in each
treatment cycle for all patients and neutropenia was categorised
using the National Cancer Institute common terminology criteria
for adverse events (CTCAE, version 2.0). Tumour response was
assessed by the Response Evaluation Criteria in Solid Tumors
(RECIST) Group criteria. Overall survival was defined as time from
randomisation until death from any cause. To evaluate the
prognostic impact of chemotherapy-induced neutropenia, we first
identified the worst grade of neutropenia during treatment for
each patient. Then, using the proportional-hazards regression
model, we estimated hazard ratios for overall survival according to
the worst grade of neutropenia, after adjustment for covariates.
The participants in the trial had advanced NSCLC and a
considerable number of patients died during the treatment period.
This can lead to serious bias and result in a false-positive
association between chemotherapy-induced neutropenia and
longer survival, because patients who die during treatment receive
fewer cycles of chemotherapy and, therefore, have less chance of
developing more severe neutropenia. To lessen this bias, we used
landmark analysis, whereby patients who died within 126 days
(i.e., six 21-day cycles) of starting chemotherapy were excluded.
Survival curves were estimated using the Kaplan–Meier method.
All reported p values are two-tailed; a value below 0.05 was
considered statistically significant. All analyses were performed
using SAS version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Incidence of neutropenia
Table 1 shows the grade of neutropenia according to treatment
cycle of chemotherapy. A total of 275 of the 387 patients died. The
median follow-up time for all patients was 393 days (range 19–
1711). One hundred and fifty-five patients (40%) completed the
planned six cycles of treatment and 308 patients (80%) had
chemotherapy-induced neutropenia: 20 patients (5%) had grade 1,
38 (10%) had grade 2, 97 (25%) had grade 3 and 153 (40%) had
grade 4 as the worst grade.
G-CSF use
Table 2 shows the use of G-CSF according to the worst grade of
neutropenia. Prophylactic use was not permitted. Nevertheless, G-
CSF was administered to 15 patients who did not have grade-3 or
greater neutropenia, or grade-4 leukopenia, so these patients were
excluded from the analysis.
Association between survival and chemotherapy-induced
neutropenia
First, the association between the worst grade of neutropenia and
the number of treatment cycles was evaluated. Patients who
experienced more severe neutropenia received more cycles of
chemotherapy (Table 3).
We then examined the causes of deaths that occurred within 126
days of the initiation of chemotherapy. Thirty-three patients died
and lung cancer was the cause of death for 26 patients. Pneumonia,
myocardial infarction, neutropenic sepsis and interstitial pneu-
monia resulting from previous radiation accounted for one death
each. The causes of three deaths were unknown. Only one patient
died from neutropenic sepsis through this clinical trial.
These data indicate that patients who had better outcomes could
receive more cycles of treatment, resulting in higher incidence of
chemotherapy-induced neutropenia. To lessen this bias, we used a
landmark analysis, excluding the 33 patients who died and two
patients who were lost to follow-up within 126 days of the
initiation of chemotherapy. Thus, data from 337 patients were
analysed: 162 patients in the VGD arm and 175 patients in the PC
arm. Since the mean number of treatment cycles for patients who
developed chemotherapy-induced neutropenia was still higher
than that for patients who had no neutropenia (Table 3), we
included the number of treatment cycles as a covariate in the
multivariate analysis. Given the size of this trial, the patients were
Table 1 The incidence of neutropenia according to treatment cycle (n¼387). Values indicate number (%) of patients
Treatment cycle 1 2 3 4 5 6 1–6
Number of patients 387 350 300 242 181 155 387
Grade 0 140 (36) 123 (35) 113 (38) 90 (37) 73 (40) 81 (52) 79 (26)
Grade 1 26 (7) 31 (9) 26 (9) 16 (7) 11 (6) 4 (3) 20 (5)
Grade 2 42 (11) 50 (14) 30 (10) 33 (14) 19 (10) 18 (12) 38 (10)
Grade 3 89 (23) 87 (25) 79 (26) 53 (22) 43 (24) 30 (19) 97 (25)
Grade 4 90 (23) 59 (17) 52 (17) 50 (21) 35 (19) 22 (14) 153 (40)
Grades 1–4 247 (64) 227 (65) 187 (62) 152 (63) 108 (60) 74 (48) 308 (80)
Table 2 The use of G-CSF according to worst grade of neutropenia
(n¼387). Values indicate number (%) of patients
Use of G-CSF
Worst grade of
neutropenia n No Yes
Grade 0 79 70 (89) 9 (11)
Grade 1 20 19 (95) 1 (5)
Grade 2 38 33 (87) 5 (13)
Grade 3 97 65 (67) 32 (33)
Grade 4 153 25 (16) 128 (84)
Abbreviation: G-CSF, granulocyte-colony-stimulating factor.
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sdistributed into three categories according to the worst grade of
neutropenia: absent (grade 0), mild (grades 1 and 2) and severe
(grades 3 and 4).
The median survival time was 10.5 months (95% confidence
interval (CI) 8.2–12.4) for the grade-0 group (n¼55), 16.6 months
(95% CI 13.8–20.7) for the grade-1 to 2 group (n¼46) and 17.8
months (95% CI 15.0–20.3) for the grade-3 to 4 group (n¼236)
(Figure 1). The baseline patient characteristics for the different
groups are shown in Table 4. Using the proportional-hazards
regression model to adjust for the imbalance of patient characteristics
among groups, we estimated hazard ratios for overall survival
according to the worst grade of neutropenia after adjustment
for covariates (sex, smoking history, stage, ECOG performance
status, weight loss, serum lactate dehydrogenase level, presence
of bone, liver or skin metastases, pretreatment absolute neutrophil
count and number of the treatment cycles as the known prognostic
factors) (Paesmans et al, 1995; Pfister et al, 2004; Teramukai et al,
2009). Patients who had chemotherapy-induced neutropenia
had lower risk of death than those who did not, although the
difference between no neutropenia and grade-3 to 4 neutropenia
was not significant. The adjusted hazard ratio compared with
the grade-0 group was 0.59 (95% CI 0.36–0.97; P¼0.036) for the
grade-1 to 2 group, and that for the grade-3 to 4 group was 0.71
(95% CI 0.49–1.03; P¼0.072) (Table 5). In both treatment arms,
the proportion of patients who moved on from VGD or PC to
second-line chemotherapy (e.g., because of progressive disease
(PD)) was almost equal among the groups distributed by the grade
of neutropenia.
We also estimated the hazard ratios for overall survival
according to the combination of worst grade of neutropenia and
best tumour response, after adjustment for the covariates listed
above (Table 6). As a preliminary step, hazard ratios according to
the best tumour response alone were calculated. The adjusted
hazard ratio for stable disease (SD) compared with partial
response (PR) as the best tumour response was 1.93 (95% CI,
1.39–2.67) and that for PD compared with PR was 3.31 (95% CI,
1.89–5.79). The adjusted hazard ratio compared with no
neutropenia with PR was 0.29 (95% CI 0.11–0.80) for grade-1 to
2 neutropenia with PR; 0.44 (95% CI 0.21–0.92) for grade-3 to 4
neutropenia with PR; 0.78 (95% CI 0.33–1.87) for grade-1 to 2
neutropenia with SD and 0.80 (95% CI 0.38–1.70) for grade-3 to 4
neutropenia with SD. The hazard ratios did not differ significantly
between the patients who developed neutropenia with SD and
those who lacked neutropenia with PR.
Table 3 Association between worst grade of neutropenia and number of treatment cycles received
Number of treatment cycles
All patients (n¼372) Patients in landmark analysis (n¼337)
Worst grade of
neutropenia n Mean±s.d. n Mean±s.d.
Grade 0 70 3.4±1.9 55 3.9±1.9
Grade 1 19 4.0±1.7 18 3.9±1.7
Grade 2 33 4.2±1.9 28 4.6±1.7
Grade 3 97 4.5±1.6 90 4.7±1.5
Grade 4 153 4.5±1.7 146 4.6±1.6
Overall survival logrank test P=0.0005
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Figure 1 Kaplan–Meier survival curves according to the worst grade of chemotherapy-induced neutropenia (landmark time¼126 days).
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sDISCUSSION
It has been reported that haematological toxicity could be a
measure of the biological activities of cytotoxic drugs. Many of us
believe that administration of larger dose of chemotherapeutic agents
over a defined period is more likely to result in success – the
patient will have more chances to go into complete or partial remis-
sion, and this will improve survival (Luciani et al, 2009). However,
several studies in the last decade have reported that larger doses of
chemotherapy do not always improve prognosis (Stadtmauer et al,
2000; Mo ¨bus et al, 2007). Using a unique time-dependent approach
to analyse data from a prospective survey of patients with
advanced gastric cancer treated with oral fluoropyrimidine S-1,
Yamanaka et al (2007) reported that survival was longest in
patients who experienced grade-2 neutropenia as the worst grade.
Here we review data from a clinical trial of patients with
advanced NSCLC. Patients who developed neutropenia showed
longer survival than those who had no neutropenia. Furthermore,
severe neutropenia (grade 3–4) was no better than mild
neutropenia (grade 1–2) for prediction of overall survival. As a
whole, these results are consistent with previous reports of the
chemotherapy of NSCLC and gastric cancer (Di Maio et al, 2005;
Yamanaka et al, 2007; Pallis et al, 2008), and strongly suggest that
neutropenia per se is not important, but the use of neutropenia to
reflect that an adequate dose has been given.
The dose of chemotherapeutic agents is usually determined on
the basis of body surface area (BSA) or creatinine clearance;
however, elimination of the agents will vary from patient to
patient because of a variety of factors such as pharmacogenetic
background (Friedman et al, 1999) and drug interactions (Relling
et al, 2000). Variation in drug elimination may explain why some
patients in this clinical trial experience severe toxicities or
inadequate antitumour effects. Absence of neutropenia may mean
that the doses of chemotherapeutic agents administered are not
enough to produce the full antitumour effect. Gurney (2002)
Table 4 Baseline patient characteristics (n¼337)
Grade 0
(n¼55)
Grade 1–2
(n¼46)
Grade 3–4
(n¼236)
Age (years)
Median (range) 63 (45–78) 64 (43–81) 65 (33–81)
Sex
Male (n) (%) 43 (78) 36 (78) 159 (67)
Female (n) (%) 12 (22) 10 (22) 77 (33)
Smoking history
Current smokers (n) (%) 25 (45) 24 (52) 91 (39)
Former smokers (n) (%) 17 (31) 9 (20) 70 (30)
Non-smokers (n) (%) 11 (20) 10 (22) 65 (28)
Unknown (n) (%) 2 (4) 3 (7) 10 (4)
NSCLC stage
IIIB (n) (%) 15 (27) 10 (22) 37 (16)
IV (n) (%) 40 (73) 36 (78) 199 (84)
ECOG performance status
0( n) (%) 16 (29) 16 (35) 112 (47)
1( n) (%) 39 (71) 30 (65) 124 (53)
Weight loss
o 5% (n) (%) 46 (84) 39 (85) 198 (84)
45% (n) (%) 9 (16) 7 (15) 38 (16)
LDH
Normal (n) (%) 40 (73) 32 (70) 172 (73)
High (n) (%) 15 (27) 14 (30) 64 (27)
Bone metastases
No (n) (%) 42 (76) 36 (78) 170 (72)
Yes (n) (%) 13 (24) 10 (22) 66 (28)
Liver metastases
No (n) (%) 52 (95) 43 (93) 217 (92)
Yes (n) (%) 3 (5) 3 (7) 19 (8)
Skin metastases
No (n) (%) 54 (98) 45 (98) 233 (99)
Yes (n) (%) 1 (2) 1 (2) 3 (1)
Pretreatment neutrophil count
Mean (per mm
3±s.d.) 5828±2211 4968±1732 4427±2275
Abbreviations: ECOG¼Eastern Cooperative Oncology Group; LDH¼lactate
dehydrogenase; NSCLC¼non-small-cell lung cancer.
Table 5 Multivariate proportional-hazards regression analysis for asso-
ciations between overall survival and worst grade of neutropenia (n¼337)
Hazards ratio 95% CI P-value
Neutropenia
Grade 0 1 — —
Grade 1/2 0.59 0.36–0.97 0.036
Grade 3/4 0.71 0.49–1.03 0.072
Sex
Male 1 — —
Female 0.75 0.53–1.06 0.104
Smoking history
Non-/former smokers 1 — —
Current smokers 1.67 1.23–2.28 0.001
Stage
IIIB 1 — —
IV 1.12 0.77–1.64 0.551
Performance status
01 — —
1 2.08 1.53–2.84 o0.0001
Weight loss
o5% 1 — —
X5% 1.06 0.74–1.50 0.765
Serum LDH
Normal 1 — —
High 1.64 1.20–2.25 0.002
Bone metastasis
No 1 — —
Yes 1.23 0.87–1.72 0.240
Liver metastasis
No 1 — —
Yes 1.62 1.02–2.60 0.043
Skin metastasis
No 1 — —
Yes 4.25 1.50–12.03 0.006
Neutrophil count
o 4500/mm
3 1— —
X4500/mm
3 1.56 1.18–2.05 0.002
Number of treatment cycles
11 — —
2 0.94 0.48–1.84 0.866
3 1.07 0.58–1.96 0.838
4 0.88 0.48–1.61 0.674
5 0.59 0.29–1.21 0.151
6 0.58 0.34–1.01 0.054
Abbreviations: CI¼confidence interval; LDH¼lactate dehydrogenase.
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spointed out a poor correlation between BSA and the pharmaco-
kinetics of anticancer agents (Newell, 2002).
From this perspective, this association also suggests that
neutropenia or other toxicities induced by chemotherapy can be
used as an indicator for planning regimens tailored to individual
patients. When we administer chemotherapy to patients, we
prepare a schedule for administration of each agent. Then, after
initiation of chemotherapy, we often reduce the planned doses of
agents in the event of severe neutropenia or other toxicities,
whereas we seldom increase the dose if a patient lacks such
toxicities. However, increasing the doses of agents to induce mild
or moderate neutropenia may be of benefit for patients who do not
show haematological or major non-haematological toxicities in the
first or second cycle of treatment.
We have previously confirmed that increased pretreatment
neutrophil count is an independent negative prognostic factor
(Teramukai et al, 2009), and we included it as one of covariates in
the present study. Tumour-related leukocytosis (neutrophilia) is
encountered occasionally in patients with NSCLC and has recently
been demonstrated to be an important negative prognostic factor
for overall survival and time to progression in patients with
NSCLC (Mandrekar et al, 2006). Although autonomous production
of G-CSF and granulocyte–macrophage-colony-stimulating factor
(GM-CSF) by tumour has been identified in some cases,
leukocytosis (neutrophilia) in NSCLC patients is not fully under-
stood and is likely to be caused by a combination of factors.
Considering the negative prognostic value of leukocytosis
(neutrophilia), it can be hypothesised that a proportion of the patients
who do not develop neutropenia during treatment may have a
poorer prognosis because they may be potentially affected by
tumour-related leukocytosis (neutrophilia) and protected from
chemotherapy-induced neutropenia (Maione et al, 2009). How-
ever, the results of our analysis suggest that chemotherapy-
induced neutropenia is a predictor independent of NSCLC-related
leukocytosis, since the risk of death estimated by the proportional-
hazards regression model was significantly lower in patients who
had grade-1 to 2 chemotherapy-induced neutropenia after adjust-
ment for covariates, including pretreatment neutrophil count.
We estimated hazard ratios for the overall survival for
subgroups assigned by the combination of the worst grade of
neutropenia and the best tumour response. Patients who
experienced neutropenia with PR as the best tumour response
showed lower risk of death than those with PR who lacked
neutropenia. The hazard ratios did not differ significantly between
the patients who developed mild or severe neutropenia with SD
and those with PR who lacked neutropenia. There are some
limitations to the assessment of tumour size using the RECIST
method or other widely used methods of assessing tumour
response to anticancer therapy. Lara et al (2008) reported the
importance of how to interpret SD and introduced the concept of
disease control rate. Results from the randomised trial (JMTO
LC00-03) and this study add further evidence that the associa-
tion between the RECIST response and overall survival may
depend on the grade of neutropenia and that the RESICT response
may not be a surrogate endpoint for overall survival of advanced
NSCLC in the chemotherapy setting (Kubota et al, 2008). Further
investigation into this association in a large-scale meta-analysis
would be helpful to resolve the important question of whether
tumour response to anticancer agents could be used as a surrogate
for overall survival in patients with advanced cancer (Ichikawa and
Sasaki, 2006).
In conclusion, we confirm that chemotherapy-induced neutro-
penia can predict survival for patients with advanced NSCLC. This
association also suggests the possibility that neutropenia, or other
chemotherapy-induced toxicities, can be used as indicators in
setting up dosage regimens that are tailored for individual patients.
Categorisation of patients according to drug elimination capacity
may be useful in determining initial dosage regimens, with
subsequent fine-tuning depending on the presence or absence of
haematological and non-haematological toxicities during early
cycles. Prospective randomised trials of early-dose increases guided
by chemotherapy-induced toxicities are, therefore, warranted.
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